Dr. Weitzel Discusses the Impact of Gene Mutations on Treatment

Video

Jeffrey N. Weitzel, MD, director, Clinical Cancer Genetics, director, Cancer Screening & Prevention Program Network, professor, City of Hope, discusses the impact of gene mutations on treatment.

Weitzel believes risk-appropriate management is important. A decade of evidence shows that removing the ovaries of young BRCA carriers almost eliminates the risk of ovarian cancer, as well as breast cancer, adds Weitzel.

There are many challenges that Weitzel and his colleagues face as they try to integrate new genes, and for every gene, there is a chance of finding a variation that is less understood.

Jeffrey N. Weitzel, MD, director, Clinical Cancer Genetics, director, Cancer Screening & Prevention Program Network, professor, City of Hope, discusses the impact of gene mutations on treatment.

Related Videos
Video 3 - "Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies"
Video 2 - "EMERALD: Underscoring Key Elacestrant Data + Subgroup Analyses for Informed Therapy Selection"
Video 1 - "A 62-Year-Old Woman with HR+ HER2-low Metastatic Breast Cancer and Lung, Liver, and Bone Metastases and Using Biomarker Testing to Guide Treatment Selection"
Related Content